Tuesday, June 26, 2018 5:16:57 PM
http://www.rmsmedicalproducts.com/wp-content/uploads/2018/06/repr-1q18-presentation.pdf
Additionally some drugs that were traditionally delivered by IV, can now be self administer at home via the RMS home infusion system. This is possible because of the new administration set with the patent pending needles.
There are many sexier technologies but REPR is a small company and has no long term debt. The company can finance its growth without issuing more shares. I expect the company will eventually be bought out at two or more times the current share price.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM